JP2008536487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008536487A5 JP2008536487A5 JP2008501411A JP2008501411A JP2008536487A5 JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5 JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- activated
- tumor cell
- atcp
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0505508.2 | 2005-03-17 | ||
| GB0505508A GB0505508D0 (en) | 2005-03-17 | 2005-03-17 | Method |
| GB0514288.0 | 2005-07-12 | ||
| GB0514288A GB0514288D0 (en) | 2005-07-12 | 2005-07-12 | Method |
| PCT/GB2006/000960 WO2006097743A2 (en) | 2005-03-17 | 2006-03-16 | Method for actvating natural killer cells by tumor cell preparation in vitro |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012224042A Division JP5906168B2 (ja) | 2005-03-17 | 2012-10-09 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2014212302A Division JP2015012876A (ja) | 2005-03-17 | 2014-10-17 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008536487A JP2008536487A (ja) | 2008-09-11 |
| JP2008536487A5 true JP2008536487A5 (https=) | 2009-03-12 |
| JP5663135B2 JP5663135B2 (ja) | 2015-02-04 |
Family
ID=36992099
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501411A Expired - Fee Related JP5663135B2 (ja) | 2005-03-17 | 2006-03-16 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2012224042A Expired - Lifetime JP5906168B2 (ja) | 2005-03-17 | 2012-10-09 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2014212302A Withdrawn JP2015012876A (ja) | 2005-03-17 | 2014-10-17 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012224042A Expired - Lifetime JP5906168B2 (ja) | 2005-03-17 | 2012-10-09 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
| JP2014212302A Withdrawn JP2015012876A (ja) | 2005-03-17 | 2014-10-17 | 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8257970B2 (https=) |
| EP (2) | EP2399594B1 (https=) |
| JP (3) | JP5663135B2 (https=) |
| AU (1) | AU2006224313B2 (https=) |
| CA (1) | CA2601197C (https=) |
| DK (1) | DK1863905T3 (https=) |
| ES (1) | ES2566335T3 (https=) |
| PL (1) | PL1863905T3 (https=) |
| WO (1) | WO2006097743A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106434527A (zh) | 2006-04-14 | 2017-02-22 | 安斯泰来再生医药协会 | 血管瘤集落形成细胞 |
| CN102046196B (zh) * | 2008-05-29 | 2014-07-30 | 特朗斯吉有限公司 | 用于选择患者的生物标志物及相关方法 |
| WO2011004201A1 (en) * | 2009-07-10 | 2011-01-13 | Mark Lowdell | Preserved compositions of activated nk cells and methods of using the same |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| SI2785359T1 (sl) | 2011-11-30 | 2018-11-30 | Astellas Institute For Regenerative Medicine | Mezenhimske stromalne celice in uporabe povezane z njimi |
| WO2013132256A1 (en) | 2012-03-07 | 2013-09-12 | Ucl Business Plc | Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals |
| US9938498B2 (en) | 2012-05-07 | 2018-04-10 | Nkmax Co., Ltd. | Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells |
| WO2013168978A1 (ko) * | 2012-05-07 | 2013-11-14 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| HK1208054A1 (en) | 2012-07-12 | 2016-02-19 | 爱姆斯坦生物技术公司 | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| CA2896053A1 (en) | 2012-12-21 | 2014-06-26 | Ocata Therapeutics, Inc. | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| CN106687584B (zh) * | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 |
| US10758567B2 (en) | 2015-09-16 | 2020-09-01 | Immune Ventures LLC | In vivo priming of natural killer cells |
| ES2871100T3 (es) * | 2015-12-07 | 2021-10-28 | Immune Ventures LLC | Cebado in vivo de linfocitos citolíticos naturales |
| US20200101106A1 (en) * | 2017-03-15 | 2020-04-02 | Immune Ventures, Llc | In vivo priming of natural killer cells |
| IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
| CN120365435A (zh) * | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| JP6838750B2 (ja) * | 2019-01-21 | 2021-03-03 | 株式会社ガイアバイオメディシン | Ｎｋ細胞を含む細胞集団の製造方法 |
| JP7713393B2 (ja) * | 2019-06-21 | 2025-07-25 | イミュニティーバイオ インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4507711A1 (en) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| KR20250118299A (ko) * | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE323756T1 (de) * | 1997-04-30 | 2006-05-15 | Hans Klingemann | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| US6849452B1 (en) * | 1998-03-03 | 2005-02-01 | Institut Gustave Roussy | Methods for activating natural killer (NK) cells and means for carrying out said methods |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
-
2006
- 2006-03-16 DK DK06726410.1T patent/DK1863905T3/en active
- 2006-03-16 JP JP2008501411A patent/JP5663135B2/ja not_active Expired - Fee Related
- 2006-03-16 AU AU2006224313A patent/AU2006224313B2/en not_active Ceased
- 2006-03-16 WO PCT/GB2006/000960 patent/WO2006097743A2/en not_active Ceased
- 2006-03-16 ES ES06726410.1T patent/ES2566335T3/es not_active Expired - Lifetime
- 2006-03-16 CA CA2601197A patent/CA2601197C/en not_active Expired - Fee Related
- 2006-03-16 EP EP11002652.3A patent/EP2399594B1/en not_active Expired - Lifetime
- 2006-03-16 PL PL06726410T patent/PL1863905T3/pl unknown
- 2006-03-16 EP EP06726410.1A patent/EP1863905B1/en not_active Expired - Lifetime
-
2007
- 2007-09-17 US US11/856,466 patent/US8257970B2/en not_active Expired - Fee Related
-
2012
- 2012-08-31 US US13/601,153 patent/US8637308B2/en not_active Expired - Fee Related
- 2012-10-09 JP JP2012224042A patent/JP5906168B2/ja not_active Expired - Lifetime
-
2013
- 2013-11-21 US US14/086,768 patent/US9655925B2/en not_active Expired - Fee Related
-
2014
- 2014-10-17 JP JP2014212302A patent/JP2015012876A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008536487A5 (https=) | ||
| Ginckels et al. | Oxidative stress and inflammation in cardiovascular diseases and cancer: role of non-coding RNAs | |
| Gkikas et al. | The role of mitophagy in innate immunity | |
| Park et al. | Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases | |
| Nehrbas et al. | Extracellular vesicles and chemotherapy resistance in the AML microenvironment | |
| Showel et al. | Advances in treating acute myeloid leukemia | |
| NO20075245L (no) | Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer | |
| Montoya et al. | Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies | |
| MX2010010726A (es) | Composicion de estilizado de cabello. | |
| Wang et al. | Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool | |
| JP2016501013A5 (https=) | ||
| JP2008519047A5 (https=) | ||
| NZ599825A (en) | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells | |
| Li et al. | ADAR1 attenuates allogeneic graft rejection by suppressing miR‐21 biogenesis in macrophages and promoting M2 polarization | |
| JP2009232853A5 (https=) | ||
| Kanat et al. | Shattering the castle walls: Anti-stromal therapy for pancreatic cancer | |
| JP2009545620A5 (https=) | ||
| Guo et al. | Betaine effects on morphology, proliferation, and p53-induced apoptosis of hela cervical carcinoma cells in vitro | |
| Baarine et al. | Pro-apoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells | |
| SG149875A1 (en) | Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds | |
| JP2018522880A5 (https=) | ||
| WO2017087947A3 (en) | Method of treatment of follicular lymphoma with a btk inhibitor | |
| Ziko et al. | Mechanical Stress Promotes Cisplatin‐Induced Hepatocellular Carcinoma Cell Death | |
| Huart et al. | Could protons and carbon ions be the silver bullets against pancreatic cancer? | |
| Kim et al. | A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells |